Understanding how certain proteins affect high-risk brain cancer in children
Deciphering non-canonical translation in high risk medulloblastoma
['FUNDING_CAREER'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10689264
This study is looking at a type of brain cancer in kids called Group 3 medulloblastoma, and it's exploring a special protein called ASNSD1 to see how it affects cancer cells, with the hope of finding new ways to treat this tough illness.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10689264 on ClinicalTrials.gov |
What this research studies
This research focuses on children with a specific type of brain cancer called Group 3 medulloblastoma, which has a high mortality rate despite current treatments. The study investigates over 2,000 non-canonical proteins that have been overlooked in previous research, particularly looking at a protein called ASNSD1 and its role in cancer cell behavior. By using advanced cell line and mouse models, the research aims to validate the importance of ASNSD1 and its interactions in the development of this aggressive cancer. The ultimate goal is to identify new therapeutic targets that could lead to better treatment options for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with Group 3 medulloblastoma.
Not a fit: Patients with other subtypes of medulloblastoma or those over 11 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that significantly improve survival rates for children with high-risk medulloblastoma.
How similar studies have performed: While the investigation of non-canonical proteins in cancer is a relatively novel approach, there have been successful studies in other cancer types that suggest this strategy could yield significant insights.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PRENSNER, JOHN — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: PRENSNER, JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancers